RxDoctor Payments Data

Willy Ky, MD

Ophthalmology · Flushing, NYNPI 1881664092

Payments from drug & device makers

$5,046in general payments, 2019–2025

Across 49 payments — averaging $102.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$4K
  • Oyster Point Pharma, Inc.$395
  • Amgen$141
  • AbbVie$110
  • Harrow Eye, LLC$106
  • Johnson & Johnson Vision Care, Inc.$45
  • plus $208 from 10 others

What the payments were for

  • Consulting fees$4,00079%
  • Food & beverage$1,02920%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,046 in reported general payments places this provider in the 75th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$98,034
Medicare patients
186
Services billed
841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine225$139,812
LumiganBimatoprost302$129,829
ProlensaBromfenac Sodium266$92,019
XdemvyLotilaner32$58,865
Prednisolone Acetate773$39,616
Bromfenac Sodium145$25,861
TyrvayaVarenicline Tartrate38$24,785
Bepotastine Besilate158$23,729
XiidraLifitegrast33$23,083
RhopressaNetarsudil Mesylate59$21,558
VyzultaLatanoprostene Bunod37$18,140
Cyclosporine72$16,216
Alphagan PBrimonidine Tartrate56$14,938
Azelastine Hcl740$12,849
RocklatanNetarsudil Mesylat/Latanoprost21$12,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$110$295,744619 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$17$93,866277 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$19$58,86532 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$18$41,22470 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$24$34,27280 claims
Oyster Point Pharma, Inc.Tyrvaya$395$24,78538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →